# Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Canonical URL: https://biopharmsignal.com/news/DYN/dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights
Ticker: DYN
Company: Dyne Therapeutics
Source: Dyne Therapeutics
Published: 2026-05-11 11:30 EST
Original Source URL: https://investors.dyne-tx.com
## Summary

- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term dystrophin data from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 DMD presented at MDA

## Article Body
- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term dystrophin data from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 DMD presented at MDA
## Recent Company News
- 2026-06-03 11:30 EST — [Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-completion-of-enrollment-in-registrational-expansion-cohort-of-achieve-trial-of-z-basivarsen-for-myotonic-dystrophy-type-1-dm1) — Source: Dyne Therapeutics
- 2026-05-26 11:30 EST — [Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-submission-of-biologics-license-application-bla-to-u-s-fda-for-z-rostudirsen-in-exon-51-duchenne-muscular-dystrophy-dmd) — Source: Dyne Therapeutics
- 2026-05-20 11:46 EST — [Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-initiation-of-phase-3-forzetto-trial-of-z-rostudirsen-in-duchenne-muscular-dystrophy-dmd-ahead-of-planned-bla-submission-for-u-s-accelerated-approval) — Source: Dyne Therapeutics
- 2026-05-11 11:30 EST — [Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/DYN/dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights) — Source: Dyne Therapeutics
- 2026-04-27 20:34 EST — [Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-upcoming-presentation-highlighting-robust-cns-activity-in-nonhuman-primates-with-its-forcetm-platform-at-2026-asgct-annual-meeting) — Source: Dyne Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)